Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLSNASDAQ:CRBPNASDAQ:EPIXNASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$1.38+0.7%$1.48$1.10▼$2.43$77.82M2.92143,339 shs36,065 shsCRBPCorbus Pharmaceuticals$8.31+0.4%$7.50$4.64▼$61.90$101.69M3.11347,221 shs68,090 shsEPIXESSA Pharma$1.69$1.71$1.40▼$7.88$75.02M1.58338,788 shs38,124 shsLSTALisata Therapeutics$2.50+4.3%$2.44$1.87▼$4.20$20.94M120,522 shs14,923 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis+0.73%-1.78%-10.97%+8.66%-32.02%CRBPCorbus Pharmaceuticals+0.36%-7.36%+7.09%+38.50%-81.03%EPIXESSA Pharma0.00%0.00%-0.59%+5.62%-63.73%LSTALisata Therapeutics+4.33%+1.79%-4.79%+9.82%-24.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis3.4145 of 5 stars3.55.00.00.02.32.50.6CRBPCorbus Pharmaceuticals3.9753 of 5 stars3.61.00.04.71.62.50.6EPIXESSA Pharma2.0774 of 5 stars2.03.00.00.02.62.51.3LSTALisata Therapeutics2.4128 of 5 stars3.53.00.00.01.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$4.00189.86% UpsideCRBPCorbus Pharmaceuticals 3.10Buy$50.88512.21% UpsideEPIXESSA Pharma 2.00Hold$2.0018.34% UpsideLSTALisata Therapeutics 3.00Buy$15.00499.04% UpsideCurrent Analyst Ratings BreakdownLatest LSTA, EPIX, CRBP, and CLLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$49.22M1.56N/AN/A$2.36 per share0.58CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AEPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/ALSTALisata Therapeutics$1M21.58N/AN/A$3.49 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)CRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)EPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)LSTALisata Therapeutics-$19.99M-$2.30N/AN/AN/AN/A-61.37%-53.35%8/11/2025 (Estimated)Latest LSTA, EPIX, CRBP, and CLLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/A5/8/2025Q1 2025LSTALisata Therapeutics-$0.53-$0.55-$0.02-$0.55N/AN/A5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.441.671.67CRBPCorbus PharmaceuticalsN/A11.8211.82EPIXESSA PharmaN/A67.1567.15LSTALisata TherapeuticsN/A7.527.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%CRBPCorbus Pharmaceuticals64.64%EPIXESSA Pharma75.12%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%CRBPCorbus Pharmaceuticals3.60%EPIXESSA Pharma15.50%LSTALisata Therapeutics9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableCRBPCorbus Pharmaceuticals4012.24 million11.80 millionOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableLSTALisata Therapeutics308.62 million7.79 millionNot OptionableLSTA, EPIX, CRBP, and CLLS HeadlinesRecent News About These CompaniesLisata and GATC to use AI for new opioid use disorder drugJune 18 at 4:15 PM | thepharmaletter.comLisata Therapeutics to lead development of opioid use disorder drug under expanded allianceJune 17 at 8:45 PM | proactiveinvestors.comLisata Therapeutics, Inc.: Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentJune 17 at 3:44 PM | finanznachrichten.deLisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC HealthJune 17 at 9:36 AM | proactiveinvestors.comLisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentJune 17 at 8:00 AM | globenewswire.comLisata Therapeutics to Present at the 2025 BIO International ConventionJune 11, 2025 | globenewswire.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comLisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ...May 10, 2025 | finance.yahoo.comLisata Therapeutics’ Earnings Call Highlights ProgressMay 9, 2025 | tipranks.comLisata Therapeutics Reports Q1 2025 Financial ResultsMay 9, 2025 | tipranks.comLisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call TranscriptMay 8, 2025 | seekingalpha.comLisata eyes key trial milestones in 2025 as certepetide development gains momentumMay 8, 2025 | proactiveinvestors.comLisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comLisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025May 1, 2025 | globenewswire.comLisata Therapeutics talks ADC breakthrough with Catalent – ICYMIApril 19, 2025 | proactiveinvestors.comLisata, Catalent partner for cancer drug researchApril 17, 2025 | uk.investing.comLisata Therapeutics signs research license with CatalentApril 15, 2025 | proactiveinvestors.comLisata Therapeutics Announces Research License with CatalentApril 15, 2025 | globenewswire.comLisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMIMarch 8, 2025 | proactiveinvestors.comLisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI TechnologyMarch 7, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLSTA, EPIX, CRBP, and CLLS Company DescriptionsCellectis NASDAQ:CLLS$1.38 +0.01 (+0.73%) Closing price 06/18/2025 03:57 PM EasternExtended Trading$1.42 +0.04 (+2.54%) As of 06/18/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Corbus Pharmaceuticals NASDAQ:CRBP$8.31 +0.03 (+0.36%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$8.56 +0.25 (+3.01%) As of 06/18/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.ESSA Pharma NASDAQ:EPIX$1.69 0.00 (0.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.72 +0.03 (+1.48%) As of 06/18/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Lisata Therapeutics NASDAQ:LSTA$2.52 +0.13 (+5.21%) As of 06/18/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
